Role of calcitonin gene-related peptide (CGRP) receptor antagonist in acute and preventive treatment of migraine.

Michał Dacka; Mateusz Sobczyk; Paulina Dąbrowska; Kamila Giżewska; Michał Żuber

doi:10.56782/pps.206

Data publikacji : 2024-07-10

Tom 22 Nr 3 (2024)

Role of calcitonin gene-related peptide (CGRP) receptor antagonist in acute and preventive treatment of migraine.

Michał Dacka

Mateusz Sobczyk

Paulina Dąbrowska

Kamila Giżewska

Michał Żuber

DOI: https://doi.org/10.56782/pps.206

Abstrakt

Migraine is the most common neurological disease in the world. It is characterized by recurrent attacks of severe headaches of a one-sided, throbbing nature, often accompanied by sensory and motor disturbances and generally associated with nausea and increased sensitivity to light and sound. Migraine treatment can be divided into emergency treatment and preventive treatment, which aims to reduce the overall frequency and severity of attacks. In the first case, nonsteroidal anti-inflammatory drugs (NSAIDs) can be used, but in some patients they do not have the desired effect. The gold standard in the fight against migraine pain are triptans (selective serotonin 5-HT1 receptor agonists), although they too are not effective in all patients. Current understanding suggests that CGRP plays a significant role in the pathophysiology of migraines. Evidence supporting this includes increased CGRP levels during migraine attacks, causing inflammation and activation of other pathophysiological processes responsible for pain. The hope for patients are CGRP receptor antagonists, which greatly expand therapeutic options.

Słowa kluczowe:

CGRP; gepants; headache; rimegepant; ubrogepant; migraine.

Inne teksty tego samego autora

Daria Żuraw, Paulina Oleksa, Mateusz Sobczyk, Kacper Jasiński, Simple Obesity in Children , Prospects in Pharmaceutical Sciences: Tom 21 Nr 2 (2023)
Mateusz Sobczyk, Daria Żuraw, Paulina Oleksa, Kacper Jasiński, Mikołaj Porzak, Michał Dacka, SGLT2 inhibitors and their possible use in prevention and treatment of neurological diseases , Prospects in Pharmaceutical Sciences: Tom 22 Nr 1 (2024)
Paulina Oleksa, Daria Żuraw, Kacper Jasiński, Mateusz Sobczyk, Mikołaj Porzak, Alicja Sodolska, Karolina Haczkur-Pawłowska, Drugs and chemical substances inducing diabetes - review of the literature , Prospects in Pharmaceutical Sciences: Tom 22 Nr 2 (2024)
Mateusz Sobczyk, Mikołaj Porzak, Daria Żuraw, Alicja Sodolska, Paulina Oleksa, Kacper Jasiński, Small intestinal bacterial overgrowth – current, novel and possible future methods of treatment and diagnosis , Prospects in Pharmaceutical Sciences: Tom 22 Nr 2 (2024)
Paulina Dąbrowska, Michał Żuber, Michał Dacka, Efficacy and Safety of Bempedoic Acid in Lipid Disorder Therapy: A Review of Clinical Trials , Prospects in Pharmaceutical Sciences: Tom 22 Nr 3 (2024)

Szczegóły

Bibliografia

Statystyki

Autorzy

Pobierz pliki

PDF

Zasady cytowania

Dacka, M., Sobczyk , M., Dąbrowska , P., Giżewska , K., & Żuber , M. (2024). Role of calcitonin gene-related peptide (CGRP) receptor antagonist in acute and preventive treatment of migraine. Prospects in Pharmaceutical Sciences, 22(3), 21–26. https://doi.org/10.56782/pps.206

Wskaźniki altmetryczne

Cited by / Share

Licencja

Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa 4.0 Międzynarodowe.

Bibliografia

Li, D.; Abreu, J.; Tepper, S.J. A Brief Review of Gepants. Curr. Pain Headache Rep. 2023, 27, 479–488. DOI: 10.1007/S11916-023-01142-1/METRICS. DOI: https://doi.org/10.1007/s11916-023-01142-1

Robbins, M.S. Diagnosis and Management of Headache: A Review. JAMA 2021, 325, 1874–1885. DOI: 10.1001/jama.2021.1640. DOI: https://doi.org/10.1001/jama.2021.1640

Richer, L.; Billinghurst, L.; Linsdell, M.A.; Russell, K.; Vandermeer, B.; Crumley, E.T.; et al. Drugs for the acute treatment of migraine in children and adolescents. Cochrane Database of Systematic Reviews 2016, 4, Art. No.: CD005220. DOI: 10.1002/14651858.CD005220.pub2. DOI: https://doi.org/10.1002/14651858.CD005220.pub2

Kowacs, P.A.; Sampaio Rocha-Filho, P.A.; Peres, M.F.P.; Edvinsson, L. The history and rationale of the development of new drugs for migraine treatment. Arq. Neuropsiquiatr. 2023, 81, 1084–1097. DOI: 10.1055/s-0043-1777723. DOI: https://doi.org/10.1055/s-0043-1777723

Olesen, J. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018, 38, 1–211. DOI: 10.1177/0333102417738202. DOI: https://doi.org/10.1177/0333102417738202

Messina, R.; Huessler, E.M.; Puledda, F.; Haghdoost, F.; Lebedeva, E.R.; Diener, H.C. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis. Cephalalgia 2023, 43(3), Art. No: 3331024231152169. DOI: 10.1177/03331024231152169. DOI: https://doi.org/10.1177/03331024231152169

Seong, J.W.; Kim, Y.; Kwon, D.R.; Yang, C.-J.; Özçakar, L. Effectiveness of Novel Sympathetic Nerve Entrapment Point Injections for Chronic Migraine: A Pilot Study. Life (Basel) 2023, 14, Art. No: 57. DOI: 10.3390/life14010057. DOI: https://doi.org/10.3390/life14010057

Yang, Y.; Chen, M.; Sun, Y.; Gao, B.; Chen, Z.; Wang, Z. Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials. CNS Drugs 2020, 34, 463–471. DOI: 10.1007/s40263-020-00715-7. DOI: https://doi.org/10.1007/s40263-020-00715-7

Ogunlaja, O.I.; Goadsby, P.J. Headache: Treatment update. E. Neurological Sci. 2022, 29, Art. No: 100420. DOI: 10.1016/J.ENSCI.2022.100420. DOI: https://doi.org/10.1016/j.ensci.2022.100420

Dodick, D.W.; Lipton, R.B.; Ailani, J.; Lu, K.; Finnegan, M.; Trugman, J.M.; et al. Ubrogepant for the Treatment of Migraine. N. Engl. J. Med. 2019, 381, 2230–2241. DOI: 10.1056/NEJMOA1813049. DOI: https://doi.org/10.1056/NEJMoa1813049

Chiang, C.C.; Fang, X.; Horvath, Z.; Cadiou, F.; Urani, A.; Poh, W.; et al. Simultaneous Comparisons of 25 Acute Migraine Medications Based on 10 Million Users’ Self-Reported Records From a Smartphone Application. Neurology 2023, 101, E2560–E2570. DOI: 10.1212/WNL.0000000000207964. DOI: https://doi.org/10.1212/WNL.0000000000207964

Singh, R.B.H.; VanderPluym, J.H.; Morrow, A.S.; Urtecho, M.; Nayfeh, T.; et al. Acute Treatments for Episodic Migraine. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 (Comparative Effectiveness Review, No. 239.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK566246/

Ashina, M.; Hansen, J.M.; Do, T.P.; Melo-Carrillo, A.; Burstein, R.; Moskowitz, M.A. Migraine and the trigeminovascular system—40 years and counting. Lancet Neurol. 2019, 18, 795–804. DOI: 10.1016/S1474-4422(19)30185-1. DOI: https://doi.org/10.1016/S1474-4422(19)30185-1

Puledda, F.; Martins Silva, E.; Suwanlaong, K.; Goadsby, P.J. Migraine: from pathophysiology to treatment. J. Neurol. 1234, 270, 3654–3666. DOI: 10.1007/s00415-023-11706-1. DOI: https://doi.org/10.1007/s00415-023-11706-1

Schoonman, G.G.; Van Der Grond, J.; Kortmann, C.; Van Der Geest, R.J.; Terwindt, G.M.; Ferrari, M.D. Migraine headache is not associated with cerebral or meningeal vasodilatation - A 3T magnetic resonance angiography study. Brain 2008, 131, 2192–2200. DOI: 10.1093/BRAIN/AWN094. DOI: https://doi.org/10.1093/brain/awn094

Altamura, C.; Brunelli, N.; Marcosano, M.; Fofi, L.; Vernieri, F. Gepants — a long way to cure: a narrative review. Neurol. Sci. 2022, 43(9), 5697-570. DOI: 10.1007/s10072-022-06184-8. DOI: https://doi.org/10.1007/s10072-022-06184-8

Curto, M.; Capi, M.; Cipolla, F.; Cisale, G.Y.; Martelletti, P.; Lionetto, L. Ubrogepant for the treatment of migraine. Expert Opin. Pharmacother. 2020, 21, 755–759. DOI: 10.1080/14656566.2020.1721462. DOI: https://doi.org/10.1080/14656566.2020.1721462

Wei, S.; Lv, H.; Yang, D.; Zhang, L.; Li, X.; Ning, Y.; et al. Drug-related side effects and adverse reactions in the treatment of migraine: a bibliometric and visual analysis. Front. Neurol. 2024, 15, Art. No: 1342111. DOI: 10.3389/fneur.2024.1342111.

Kopka, M. Gepanty drugiej generacji w leczeniu migreny-analiza wyników randomizowanych badań kontrolowanych [Second-generation gepants in the treatment of migraine-a review of the findings of randomised controlled trials] Aktualn. Neurol. 2022, 22 (4), 180–184. DOI: . DOI: https://doi.org/10.15557/AN.2022.0022

Tepper, S.J. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment. Headache 2018, 58, 238–275. DOI: 10.1111/head.13379. DOI: https://doi.org/10.1111/head.13379

Vo, P.; Fang, J.; Bilitou, A.; Laflamme, A.K.; Gupta, S. Patients’ perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom. J. Headache Pain 2018, 19, Art. No: 82. DOI: 10.1186/S10194-018-0907-6. DOI: https://doi.org/10.1186/s10194-018-0907-6

Bigal, M.; Borucho, S.; Serrano, D.; Lipton, R. The acute treatment of episodic and chronic migraine in the USA. Cephalalgia 2009, 29, 891–897. DOI: 10.1111/J.1468-2982.2008.01819.X. DOI: https://doi.org/10.1111/j.1468-2982.2008.01819.x

Bonafede, M.; Sapra, S.; Shah, N.; Tepper, S.; Cappell, K.; Desai, P. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States. Headache 2018, 58, 700–714. DOI: 10.1111/HEAD.13275. DOI: https://doi.org/10.1111/head.13275

Leonardi, M.; Raggi, A.; Bussone, G.; D’Amico, D. Health-related quality of life, disability and severity of disease in patients with migraine attending to a specialty headache center. Headache 2010, 50, 1576–1586. DOI: 10.1111/J.1526-4610.2010.01770.X. DOI: https://doi.org/10.1111/j.1526-4610.2010.01770.x

Hagan, J.C. Systematic Review and Meta-analysis of Acute Treatments for Episodic Migraine in Adults. JAMA 2021, 326(16), 1636. DOI: 10.1001/jama.2021.14060. DOI: https://doi.org/10.1001/jama.2021.14060

Chiang, C.C.; Schwedt, T.J. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine—The monoclonal antibodies and gepants. Prog. Brain Res. 2020, 255, 143–170. DOI: 10.1016/bs.pbr.2020.06.019. DOI: https://doi.org/10.1016/bs.pbr.2020.06.019

MacDonald, D.I.; Jayabalan, M.; Seaman, J.; Nickolls, A.; Chesler, A. Pain persists in mice lacking both Substance P and CGRPα signaling. BioRxiv 2023.11.15.567208; doi: https://doi.org/10.1101/2023.11.15.567208 DOI: https://doi.org/10.1101/2023.11.15.567208

Linde, M.; Gustavsson, A.; Stovner, L.J.; Steiner, T.J.; Barré, J.; Katsarava, Z.; et al. The cost of headache disorders in Europe: The Eurolight project. Eur. J. Neurol. 2012, 19, 703–711. DOI: 10.1111/J.1468-1331.2011.03612.X. DOI: https://doi.org/10.1111/j.1468-1331.2011.03612.x

Moreno-Ajona, D.; Chan, C.; Villar-Martínez, M.D.; Goadsby, P.J. Targeting CGRP and 5-HT1F Receptors for the Acute Therapy of Migraine: A Literature Review. Headache 2019, 59, 3–19. DOI: 10.1111/HEAD.13582. DOI: https://doi.org/10.1111/head.13582

Buse, D.C.; Manack, A.; Serrano, D.; Turkel, C.; Lipton, R.B. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J. Neurol. Neurosurg. Psychiatry 2010, 81, 428–432. DOI: 10.1136/JNNP.2009.192492. DOI: https://doi.org/10.1136/jnnp.2009.192492

Peroutka, S.J. Neurogenic inflammation and migrane: Implications for therapeutics. Mol. Interv. 2005, 5, 304–311. DOI: 10.1124/MI.5.5.10. DOI: https://doi.org/10.1124/mi.5.5.10

Goadsby, P.J. The pharmacology of headache. Prog. Neurobiol. 2000, 62, 509–525. DOI: 10.1016/S0301-0082(00)00010-1. DOI: https://doi.org/10.1016/S0301-0082(00)00010-1

Blair, H.A. Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine. CNS Drugs 2023, 37, 255–265. DOI: 10.1007/s40263-023-00988-8. DOI: https://doi.org/10.1007/s40263-023-00988-8

González-Hernández, A.; Marichal-Cancino, B.A.; MaassenVanDenBrink, A.; Villalón, C.M. Side effects associated with current and prospective antimigraine pharmacotherapies. Expert Opin. Drug Metab. Toxicol. 2018, 14, 25–41. DOI: 10.1080/17425255.2018.1416097. DOI: https://doi.org/10.1080/17425255.2018.1416097

Vanderpluym, J.H.; Halker Singh, R.B.; Urtecho, M.; Morrow, A.S.; Nayfeh, T.; Torres Roldan, V.D.; et al. Acute Treatments for Episodic Migraine in Adults: A Systematic Rweview and Meta-analysis. JAMA 2021, 325, 2357–2369. DOI: 10.1001/JAMA.2021.7939. DOI: https://doi.org/10.1001/jama.2021.7939

Burch, R.; Rayhill, M. Acute Treatment for Migraine: Contemporary Treatments and Future Directions. JAMA 2021, 325, 2346–2347. DOI: 10.1001/jama.2021.7275. DOI: https://doi.org/10.1001/jama.2021.7275

de Vries, T.; Villalón, C.M.; MaassenVanDenBrink, A. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol. Ther. 2020, 211, Art. No: 107528. DOI: 10.1016/j.pharmthera.2020.107528. DOI: https://doi.org/10.1016/j.pharmthera.2020.107528

Schoenen, J.; Manise, M.; Nonis, R.; Gérard, P.; Timmermans, G. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention. Rev. Neurol. (Paris) 2020, 176, 788–803. DOI: 10.1016/j.neurol.2020.04.027. DOI: https://doi.org/10.1016/j.neurol.2020.04.027

Moisset, X.; Demarquay, G.; Ducros, A. Systematic Review and Meta-analysis of Acute Treatments for Episodic Migraine in Adults. JAMA 2021, 326, 1636–1637. DOI: 10.1001/jama.2021.14063. DOI: https://doi.org/10.1001/jama.2021.14063

Yang, C.P.; Liang, C.S.; Chang, C.M.; Yang, C.C.; Shih, P.H.; Yau, Y.C.; et al. Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine A Systematic Review and Meta-analysis. JAMA Netw Open 2021, 4(10), Art. No: e2128544. DOI: 10.1001/jamanetworkopen.2021.28544. DOI: https://doi.org/10.1001/jamanetworkopen.2021.28544

Moreno-Ajona, D.; Pérez-Rodríguez, A.; Goadsby, P.J. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment? Curr. Opin. Neurol. 2020, 33, 309–315. DOI: 10.1097/WCO.0000000000000806. DOI: https://doi.org/10.1097/WCO.0000000000000806

Ailani, J.; Lipton, R.B.; Goadsby, P.J. et al.; ADVANCE Study Group: Atogepant for the preventive treatment of migraine. N. Engl. J. Med. 2021, 385(8), 695–706. DOI: 10.1056/NEJMoa2035908 DOI: https://doi.org/10.1056/NEJMoa2035908

Croop, R.; Goadsby, P.J.; Stock, D.A. et al.: Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 2019, 394 (10200), 737–745. doi: 10.1016/S0140-6736(19)31606-X DOI: https://doi.org/10.1016/S0140-6736(19)31606-X